|
|
Volumn 98, Issue 393, 1998, Pages 109-117
|
|
The nature and duration of treatment for GAD
|
|
Author keywords
Chronicity; Generalized anxiety disorder; Long term treatment
|
|
Indexed keywords
ABECARNIL;
ALPIDEM;
BENZODIAZEPINE DERIVATIVE;
BRETAZENIL;
BUSPIRONE;
DIAZEPAM;
IMIPRAMINE;
LORAZEPAM;
MONOAMINE OXIDASE INHIBITOR;
SEROTONIN 1A ANTAGONIST;
SEROTONIN 2 ANTAGONIST;
SEROTONIN 3 ANTAGONIST;
SEROTONIN UPTAKE INHIBITOR;
ZOPICLONE;
ANTIDEPRESSANT AGENT;
ANXIOLYTIC AGENT;
ANXIETY NEUROSIS;
ARTICLE;
CHRONIC DISEASE;
CLINICAL FEATURE;
COGNITIVE DEFECT;
DRUG CHOICE;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERANCE;
HUMAN;
LONG TERM CARE;
PSYCHOTHERAPY;
ANXIETY DISORDER;
MULTIMODALITY CANCER THERAPY;
PSYCHOLOGICAL ASPECT;
REVIEW;
TREATMENT OUTCOME;
ANTI-ANXIETY AGENTS;
ANTIDEPRESSIVE AGENTS;
ANXIETY DISORDERS;
BENZODIAZEPINES;
COMBINED MODALITY THERAPY;
HUMANS;
LONG-TERM CARE;
PSYCHOTHERAPY;
TREATMENT OUTCOME;
|
|
EID: 0031723359
PISSN: 00651591
EISSN: None
Source Type: Journal
DOI: 10.1111/j.1600-0447.1998.tb05975.x Document Type: Article |
|
Times cited : (10)
|
|
References (78)
|
